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Abstract
Background: The role of fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) scanning
in operable pancreas cancer is unclear. We, therefore, wanted to investigate the impact of PET/CT on
management, by incorporating it into routine work-up.
Methods: This was a single-institution prospective study. Patients with suspected and potentially
operable pancreas, distal bile duct or ampullary carcinomas underwent PET/CT in addition to routine
work-up. The frequency that PET/CT changed the treatment plan or prompted other investigations was
determined. The distribution of standard uptake values (SUV) among primary tumours, and adjacent to
biliary stents was characterised.
Results: Fifty-six patients were recruited. The surgical plan was abandoned in 9 (16%; 95% CI: 6–26)
patients as a result of PET/CT identified metastases. In four patients, metastases were missed and
seven were inoperable at surgery, not predicted by PET/CT. Unexpected FDG uptake resulted in seven
additional investigations, of which two were useful. Among primary pancreatic cancers, a median SUV
was 4.9 (range 2–12.1). SUV was highest around the biliary stent in 17 out of 28 cases. PET/CT
detected metastases in five patients whose primary pancreatic tumours demonstrated mild to moderate
avidity (SUV < 5).
Conclusions: PET/CT in potentially operable pancreas cancer has limitations. However, as a result of
its ability to detect metastases, PET/CT scanning is a useful tool in the selection of such patients for
surgery.
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Introduction
Adenocarcinoma of the pancreas is a highly malignant disease
with a poor prognosis. Currently, in Australia, around 2500
people are diagnosed annually representing around 2.5% of all
non-cutaneous cancers. The incidence rate is higher in males
than females (1.3:1) and has been approximately stable (12
cases per 100 000 males) from 1980 to 20101. Absolute num-
bers of patients diagnosed are progressively rising, mainly as a
result of an ageing population as well as population growth.
The majority of patients have advanced disease at diagnosis,
are treated with palliative intent chemotherapy and/or radio-
therapy and have a median survival time measured in months.
For the 20% of patients with operable disease, surgery usually
involves a Whipple’s procedure that carries a morbidity risk
and may be associated with a prolonged recovery time. In pro-
spective clinical trials, only around 10–20% of such patients
are alive and cancer free 2 years after surgery, with 6 months
of adjuvant gemcitabine or 5-fluorouracil associated with a
modest survival benefit.2,3
In view of the risks associated with major surgery and the
high relapse rate, methods to better select patients most likely
to benefit from such curative intent treatment are needed.
Currently, operability assessment is based on high-quality
multi-phase CT scanning to assess the tumour relationship
with major vascular structures and to look for metastatic dis-
ease. Other investigations such as endoscopic ultrasound,
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ERCP, MRI and laparoscopy are utilized in selected patients.
FDG–PET is an established staging tool in many tumours such
as non-small cell lung cancer, oesophageal cancer and mela-
noma,4 where it facilitates more accurate staging, resulting in a
proportion of patients being spared futile surgery. The addition
of contemporaneous non-enhanced CT (PET/CT) scanning
facilitates anatomical localization with resultant increased
diagnostic accuracy.5,6 However, the role of PET/CT in staging
pancreas cancer is less well defined.7 We postulated that
PET/CT may be of a similar clinical value in operable pancreas
cancer patients. We also considered PET/CT may detect
unrelated and possibly less relevant pathology leading to
additional, potentially unnecessary, investigations.8
Tumours resulting from primary pancreatic adenocarcinomas
may largely consist of fibrotic stroma rather than malignant cells,
and this may impact on their FDG avidity. There are few data
detailing the SUV of primary pancreatic adenocarcinomas.
Moreover, inflammation is a well-recognized, non-malignant,
cause of FDG uptake. We hypothesized that biliary stents might
induce an inflammatory response that might result in FDG
uptake and confound the interpretation of the scan.
The primary objective of this study was to assess the impact
of PET/CT on management decisions, when added to the
standard work-up of patients with resectable, pancreas or peri-
ampullary cancers. Secondary objectives were to define the
FDG avidity of primary pancreatic neoplasms and around
indwelling biliary stents (as measured by maximum SUV).
Patients and methods
Study design
This was a prospective, single-institution, observational, cohort
study. This manuscript was written with reference to the
Strengthening the Reporting of Observational Studies in Clinical
Epidemiology (STROBE) statement.9
Patients were recruited between March 2008 and December
2012. All patients referred to the Royal Brisbane and Women’s
Hospital with a diagnosis of pancreatic cancer received standard
work-up consisting of a contrast-enhanced, dual-phase CT
scan of the chest, abdomen and pelvis. Other investigations/
procedures were performed as deemed clinically appropriate,
including ERCP, biliary stenting, Primovist enhanced MRI,
endoscopic ultrasound and laparoscopy. Results of these investi-
gations were discussed, and a management plan documented, at
a multidisciplinary team (MDT) meeting consisting of hepatob-
iliary surgeons, medical and radiation oncologists, interventional
and diagnostic radiologists and gastroenterologists.
Eligible patients for this study had a clinical diagnosis of
resectable pancreas, ampullary or distal bile duct adenocarci-
noma, with or without biopsy confirmation, who were fit for,
and planned to undergo, surgical resection. Resectability was
defined using the criteria of Katz/Varadhachary.10 As such, a
normal tissue plane was required between the tumour and
the superior mesenteric, coeliac and common hepatic arteries.
Surrounding (peri-pancreatic) lymphadenopathy was allowed if
the surgeons felt this would be within the resection field.
Patients with either no evidence of metastatic disease or inde-
terminate findings on standard work-up were eligible. Patients
were excluded if they had a confirmed or suspected diagnosis
of a pancreatic neuroendocrine tumour, would not be available
for post-operative follow-up or if they had any contraindica-
tions to undergoing a PET/CT scan, such as uncontrolled
diabetes. After discussion at the MDT, eligible patients were
approached to enrol into the study. Written, informed consent
was obtained, after which a PET/CT scan was performed. All
patients underwent PET/CT prior to receiving any treatment.
With the results of the PET/CT scan available, the updated
management plan was documented, noting whether any change
to the pre-PET treatment plan was made. Additionally, any fur-
ther investigations performed based on the PET/CT findings
were recorded, including those performed owing to unexpected
FDG uptake. Any independent pathology diagnosed following
these investigations was also recorded. The investigators subse-
quently determined whether any such pathology was clinically
relevant in the setting of newly diagnosed pancreatic, ampullary
or distal bile duct cancers.
As eligible patients were already diagnosed with operable
malignancy, the FDG uptake in the primary tumour or around
the biliary stent was not intended to aid in the diagnosis of the
primary tumour and had no influence on patient management.
Patients were subsequently followed up by the treating
clinicians. No further PET/CT scans were planned. Adjuvant
chemotherapy was administered at the discretion of the treat-
ing oncologist. If there was no histological verification of foci
of abnormal uptake on PET/CT, lesions were followed up by
appropriate means over time in order to clarify the aetiology.
The protocol was approved by the Royal Brisbane Hospital
Ethics Committee and all patients provided written, informed
consent. This research project is registered on the Australia and
new Zealand Clinical trials registry: ACTRN12607000604404.
PET/CT imaging protocol
PET/CT scanning followed standard departmental guidelines.
Patients fasted for a minimum of 6 h and serum glucose levels
were measured on arrival into the department. FDG was injected
at a dose of 5–7 MBq/kg. Patients remained in a relaxed position
for 1 h before PET emission data were acquired from the base of
the skull to the upper thighs. Prior to PET emission data acquisi-
tion, non-contrast CT scanning was performed for emission data
attenuation correction and anatomical localization. Standard
uptakes values (SUV) were measured.
The images were read by a specialist credentialed for PET
interpretation by the Joint Nuclear Medicine Credentialling and
Accreditation Committee of the Royal Australasian College of
Physicians and the Royal Australasian College of Radiologisits.
The PET scans of all patients with a primary pancreatic can-
cer (patients subsequently found to have benign disease were
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excluded) were retrospectively analysed by one nuclear medi-
cine physician (DM), who was blinded to clinical outcomes.
SUV max values were determined in the region of the tumour,
with the assistance of the contemporaneous CT and the con-
trast enhanced CT scan. In patients with an indwelling biliary
stent, the SUV max was also calculated around the stent. In
cases where the primary tumour was separate from the stent,
two SUV’s were calculated.
Statistical analysis
The primary endpoint of the study was to determine the
frequency that PET/CT detected occult metastatic disease hence
avoiding futile surgery. Secondary endpoints were: (i) to
determine the frequency that PET/CT findings led to further
investigations, the outcome of these and their contribution to
the overall care of the patient; and (ii) to determine the SUV
of the primary tumours and, in patients with indwelling biliary
stents, determine the SUV around the stent.
The percentage of patients in whom management decisions
are changed as a result of the PET/CT scan, with 95% confidence
intervals (CIs), were calculated. We aimed to recruit 63 evaluable
patients as if PET/CT resulted in 15% of patients avoiding futile
surgery, then this number would result in a 95% CI of between
6% and 24%. This was felt to represent a clinically meaningful
range, and the recruitment of this number of evaluable patients
was deemed feasible for our institution.
The median SUV (and range) was calculated for all patients,
those non-stented and around the biliary stent.
Results
Between March 2008 and December 2012, 56 patients were
recruited to the study. The study was closed to recruitment at
this time as recruitment was slower than expected, and PET/
CT scanner availability for research purposes became limited.
Table 1 lists the patient characteristics. The majority were
male, and the head of the pancreas was the commonest
primary site. A biliary stent was placed in 35 patients (63%)
prior to the PET/CT scan. In 9% of the patients, the primary
tumour was in the distal common bile duct and in a further
4%, the Ampulla. Two patients received neoadjuvant chemo-
therapy on a separate protocol, and PET/CT did not alter their
management. No other patient received any pre-operative
therapy. No patients were lost to follow-up.
Three patients ultimately turned out to have benign disease. A
65-year-old male presented with obstructive jaundice and a CT
cholangiogram suggested a distal common bile duct stricture
with a surrounding mass. The PET/CT scan was normal. He
underwent a Whipple’s operation and grade 2 pancreatic intra-
epithelial neoplasia, without invasive carcinoma, was found. The
second patient, a 69-year-old male presented with right upper
quadrant pain and weight loss. Liver function tests were
abnormal but there was no jaundice. A CT scan demonstrated a
head of pancreas mass and on PET/CT scan the SUV max was
3.8. At laparotomy, a large unresectable mass was found extend-
ing to the liver hilum and surrounding the superior mesenteric
vein. Biopsies revealed lymphocytic sclerosing cholangitis.
Immunoglobulin G 4 levels were normal. The patient remains
well to date. The third patient was a 75-year-old male who
presented with obstructive jaundice and imaging consistent with
a high-grade distal common bile duct stricture. ERCP failed so
he underwent a cholecystojejunostomy. A PET/CT scan was
normal. No tissue diagnosis was obtained and the patient refused
a Whipple’s procedure. The patient remains quite well 3 years
later notwithstanding recurrent episodes of cholangitis. A non-
malignant stricture was, therefore, presumed.
Patient flow through the study is depicted in the consort
diagram (Figure 1). In 9 out of 56 patients (16%; 95% CI
6–26) PET/CT scanning resulted in planned surgical treatment
being abandoned as a result of detecting unexpected metastatic
disease. The details of these nine cases are listed in Table 2.
They all had pancreatic carcinoma. As expected, metastases
were commonly picked up in the liver (5/9 cases). However, in
three patients metastases were detected in lymph nodes above
the diaphragm (mediastinum/neck), two of which were subse-
quently biopsy proven. Bone metastases were detected in one
patient, in the setting of widespread nodal disease.
No cases of peritoneal metastases were detected by PET/CT
scanning but two patients were found to have peritoneal
metastases at subsequent staging laparoscopy. Two further
patients were found to have liver metastases at the time of
definitive resection, neither of which were detected on the
PET/CT scan.
A total of seven patients were found to have locally
advanced/inoperable disease at the time of definitive laparotomy.
Table 1 Patient characteristics (n = 56)
Number (%)
Age
Median = 64
Range: 35–84
Gender
Male 41 (73)
Female 15 (27)
Location of carcinoma
Pancreas
Head 40 (71)
Body 4 (7)
Tail 2 (4)
Distal bile duct 5 (9)
Ampulla 2 (4)
Benign 3 (5)
Stented at time of PET 35 (63)
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In none of these cases did the PET/CT scan assist in predicting
this eventuality.
Table 3 lists the 10 patients in which unexpected uptake was
found on the PET/CT scan. In two of these cases, the PET/CT
was valuable as possible nodal pathology in the mediastinum/
neck was demonstrated which subsequently proved to be meta-
static adenocarcinoma (listed also in Table 2). Among five
patients, unexpected FDG uptake resulted in other investiga-
tions which were ultimately considered to have added little or
no clinical value, including sigmoidoscopy, colonoscopy,
thyroid and axillary node biopsies and excision of a squamous
cell carcinoma of the cheek. A further patient required
additional history taking to confirm sialadenitis and finally,
one patient underwent additional, careful inspection of the
pancreatic tail/adjacent small bowel at the time of the
Whipple’s procedure, with nothing found.
The median SUV of the primary tumour for all patients
with pancreatic malignancy (n = 46) was 4.9 (range 2–12.1);
for non-stented patients (n = 18) it was 4.2 (range 2.3–11.5)
and around the biliary stent (n = 28) it was 3.4 (range 2–11).
Among the stented patients, the SUV was highest at the stent
in 17 and in three of these, a separate tumour mass with lower
SUV was discernable. However, the other 11 stented patients
had a discernable, separate tumour mass exhibiting a higher
SUV than at the stent.
Among the seven patients with distal common bile duct/
ampullary tumours, the SUV max ranged from 1.5 to 6.7. In five
cases, uptake was only seen at around the stent whereas in two
patients a separate tumour with higher SUV was discernable.
Among the nine patients in which PET/CT scanning resulted
in the abandonment of surgical management (by demonstrat-
ing metastatic disease), SUV in the primary pancreatic tumours
ranged from 3.5 to 12.1 and was five or below (i.e. mild-mod-
erate uptake) in five patients (see table 2). Five of the nine
patients were stented and in three of these the region with the
highest SUV was around the stent.
Surgery abandoned as 
a result of PET 
findings 
N = 9 
See table 2 
N = 47 Did not proceed to 
surgery n = 8 
Decided inoperable: n = 4 
Metastases found at laparoscopy:  
n = 2 
not deemed fit enough: n = 1 
patient refused: n =1 
Proceeded to surgery 
N = 39 
Resected 
N = 28 
Not Resected  
n = 11 
benign on biopsy: n = 1 
diagnosed as benign: n = 1 
(bypassed) 
unresectable: n =7 
hepatic metastases discovered: 
n = 2
Malignant 
N = 27 
Benign 
N = 1 
Unanticipated 
findings on PET. 
N = 10 
See table 3 
NO 
Yes 
56 patients enrolled 
Figure 1 FlowDiagram of the study
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Discussion
We conducted this prospective study to investigate the role
PET/CT scanning in the management of patients with operable
pancreas, ampullary or distal bile duct carcinomas. In addition
to impact on surgical decision making, we wanted to explore
the impact on management more generally, such as any
independent, unexpected, pathology detected by PET/CT. As a
separate objective, we investigated the SUV characteristics of
primary pancreatic tumours. We envisioned that indwelling
biliary stents might impact image interpretation, conceivably
by inducing an inflammatory response, therefore, we specifically
measured SUV’s around these stents.
Table 2 Patients in whom surgery was abandoned as a result of PET/CT
Patient PET/CT result CT size*/CA19.9#
(other CT findings)
Comments
1 56-year-old female Low grade uptake in
HOP. SUV 3.5.
Avid uptake in segment
3 liver metastasis
48 mm
2200
Liver metastasis not seen
on standard imaging.
Lesion became
apparent on CT during
palliativechemotherapy
2 82-year-old male Mild-moderate uptake
HOP. SUV 4.9.
Moderate uptake in
para-aortic lymph node
35 mm
660
Node not seen on prior
imaging. Died of metastatic
disease 16 months later
3 34-year-old male.
Swachman
diamond syndrome
Moderate uptake in
HOP. SUV 4.7.
2 hepatic metastases
22 mm
140
Subtly visible on CT but
PET/CT confirmed
metastases. Patient
died 8 months later
of metastases
4 77-year-old male Avid uptake HOP. SUV 12.1.
2 peripheral right sided
hepatic metastases
30 mm
360
No metastases seen on
CT. Died 12 months
later of metastatic
disease
5 54-year-old male Avid uptake body of
pancreas. SUV 7.77
Avid mediastinal, cervical
nodes and multiple bone
metastases
20 mm
44 000
(Prominent node
right of SMA)
Sclerotic lesions seen on
CT but metastases
confirmed by PET and
subsequently by MRI.
Patient died 4 months later
6 75-year-old male Mild-moderate uptake
HOP. SUV 5. Liver
(segment 5), para-aortic
node and posterior
mediastinal node avid
uptake consistent with
metastases
28 mm
110
Mildly enlarged para-aortic
nodes and multiple
hepatic cysts seen on
CT and MRI. Patient
died 2 months later of
gastrointestinal haemorrhage
7 47-year-old female Mild- moderate avidity
HOP. SUV 4.5
Low to moderate avidity
in peri- pancreatic node.
Avid posterior mediastinal
lymph node 7 mm size
15 mm
350
(34 mm nodal mass
superior to pancreatic head)
Mediastinal node not seen
on CT. Thoracoscopic
biopsy of node confirmed
adenocarcinoma
8 58-year-old female Avid HOP. SUV 11.5 Avid
peri-pancreatic nodes.
Avid nodes within
mediastinum, lung hilar
supraclavicular and
cervical nodes
46 mm
10 000
(enlarged 2 cm nodes
around pancreas head)
Mildly enlarged nodes in
chest/neck on
CT (10-13 mm).
Excision biopsy of
cervical nodes revealed
sarcoidosis and
adenocarcinoma. Died
4 months later
9 65-year-old male Avid HOP lesion. SUV 8.1
Moderate uptake
segment 2/3 lesion
consistent with metastasis
No discrete mass identified.
200 (dilated common
bile duct)
Liver metastasis not seen
on initial CT but developed
on subsequent imaging.
Alive with disease
18 months later
HOP = Head of pancreas; SUV = Standard Uptake Value in the primary pancreatic tumour.
*Maximum size of the primary tumour.
#Ca 19.9 measured in KU/l (normal is <35KU/l).
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We have shown that PET/CT aided the correct decision to
abandon potentially morbid and futile surgery in 9/56 patients
(16%). This frequency is similar to that seen in diseases where
PET/CT has become part of routine management such as non-
small cell lung and oesophageal cancers.4,5 As such, our data
support the incorporation of PET/CT scanning into the
routine work-up of these patients. The CT or MRI images in
some of the 9 patients demonstrated findings that could be
construed as suspicious for metastases, such as mildly enlarged
nodes, small hepatic hypodensities and sclerotic bone lesions
(see Table 2) and might have been confirmed using another
imaging/investigative modality. This reflects the clinical dilem-
mas faced by the MDT. In all cases, the scans were reviewed at
the MDT meeting, and the patients were declared as being
operable. In this setting, the PET/CT was able to clarify the
staging and/or direct subsequent confirmatory investigations.
In addition to detecting hepatic metastases, PET/CT detected
metastases to multiple, disparate nodal groups (retroperitoneal,
mediastinal, supraclavicular and cervical) as well as to the
bone. As illustrated in Table 2, a highly FDG avid primary
tumour is not a prerequisite to the detection of metastases,
with the primary tumour in five patients exhibiting an SUV of
five or less. In all nine patients, the primary tumour was in the
pancreas. The number of patients in this study with ampullary
or distal bile duct cancers is too low to make any conclusions
regarding the relative utility of PET/CT by primary site.
PET/CT scanning, in this clinical scenario, has shortcomings.
It was of no use in predicting locally unresectable disease,
which was found at the time of surgery in seven patients. In
addition, PET/CT missed two cases each of hepatic and perito-
neal metastases. Failure to detect inoperable, locally advanced
disease is unsurprising given the limited FDG uptake of many
primary pancreatic tumours and the inability of PET/CT to
accurately define tumour extent relative to surrounding tissues.
It is well documented that metastases to the liver and perito-
neum, especially when small, can be missed by PET/CT, as has
been reported in this specific setting.11,12 It remains to be seen
if these shortcomings can be surmounted by contemporaneous
contrast enhanced CT and/or MRI scanning, and this should
be the subject of future research.
Our findings of the utility of PET/CT scanning are sup-
ported by other prospective cohorts; however, some retrospective
analyses have found no value of PET in patient management.
In a retrospective analysis, but of prospectively collected data,
Heinrich et al. found that PET/CT scanning detected metasta-
ses in 5/59 pancreatic cancer patients, changed management in
16% and was cost effective. A prospective study by Kauhanen
et al. also supports the utility of PET/CT. This group
compared PET/CT with MRI and CT scanning. They found
that PET/CT was more sensitive in detecting metastases and
changed the management strategy in 10 of 38 cases.13 By
contrast, Pappas et al.14 found that FDG PET (without concur-
rent CT) provided no additional information in 98% of 124
patients with resectable, borderline resectable or locally
advanced pancreas cancer. Matsumoto et al.7came to a similar
conclusion from their retrospective analysis.
Current NCCN guidelines state that the role of PET/CT in
the work-up of pancreas cancer patients is unclear but could
be considered following a formal pancreas protocol CT in
high-risk patients.15 Such patients are defined as having
borderline resectable disease, large primary tumours, surround-
ing lymphadenopathy or markedly elevated Ca 19.9. It would
be very useful if a patient subgroup with a higher chance of
harbouring detectable metastases at the time of investigative
work-up could be identified. While our dataset cannot conclu-
sively identify such a group, all nine patients in whom PET/CT
changed the treatment plan and resulted in surgery being
abandoned met at least one of these criteria. CA 19.9 was
Table 3 Patients with unexpected FDG uptake
Site of uptake Subsequent investigations Comments/outcome
1 Left parotid and submandibular glands Nil Further history revealed known sialadenitis
2 Ascending colon Colonoscopy Tubular adenoma with low grade dysplasia
3 Mild uptake over left cheek Excision of skin lesion left cheek Squamous cell carcinoma left cheek
4 Mild uptake right upper lobe nodule Nil Decided patient unfit for whipples regardless
of lung nodule
5 Abnormal uptake around pancreatic tail.
?Small bowel neoplasia. Primary
HOP mass avid
Inspected intraoperatively Nil found in this region. Proceeded to successful whipples
6 Left axillary node-moderate uptake Node biopsied Normal lymph node
7 Right thyroid lobe Biopsied Benign. Colloid and haemosiderin laden macrophages
8 Descending colon/sigmoid colon Sigmoidoscopy Previous surgery for diverticular disease.
Normal anastomosis. No lesion seen
9 Posterior mediastinal node Biopsied Adenocarcinoma
10 Widespread lung hilar, mediastinal
and cervical nodes
Cervical nodes biopsied Sarcoidosis and adenocarcinoma
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raised by at least three times the upper limit of normal in all
nine patients. While biliary obstruction contributes to a
raised CA19.9, the bilirubin was normal in four of these
patients. However, in three patients the primary tumour was
2 cm or less (T1 according to the 7th edition of the American
Joint Committee on Cancer staging) and in six patients no
surrounding lymphadenopathy was seen.
In comparison to other tumour sites, the true impact of
PET/CT on the treatment of pancreatic cancer might be
diluted as patients may not proceed to resection regardless of
whether they undergo a PET/CT scan. For example, locally
advanced disease or occult peritoneal/hepatic metastatic disease
may be discovered intra-operatively. In addition, owing to the
morbidity and low cure rates associated with surgery, together
with patient co-morbidities surgeons may cogitate on the value
of surgery before ultimately deciding not to proceed. In our
cohort, 11 patients were subsequently found to harbour occult
metastases or be unresectable and a further five were ultimately
deemed unsuitable for surgery, in spite of the PET/CT scan
being consistent with localized disease.
Unexpected FDG uptake raises the possibility of independent
pathology, including second primary neoplasms. This is partic-
ularly true for the colon8. We examined this phenomenon in
our cohort. PET/CT scanning resulted in several patients
undergoing additional investigations (Table 3). It can be
argued that these ultimately were unnecessary and did not pos-
itively contribute to the overall care of these patients, in the
setting of a diagnosis of pancreatic cancer. If PET/CT scanning
was to be routinely introduced into the work-up, it will be
important to bear this in mind and carefully consider the value
and appropriate timing of any additional investigations
prompted by PET/CT scanning.
Analysis of the SUV range of our cohort demonstrates that
it is not uncommon for uptake to be physiologic or only
mildly elevated in primary pancreatic carcinomas. Although
this did not influence diagnosis or management in our study
population, it suggests, in other clinical settings, that PET/CT
is not useful for defining the nature of a primary pancreatic
mass. This is best achieved using spiral enhanced CT, MRI
and/or endoscopic ultrasound. The literature is somewhat con-
flicting on this issue. The retrospective analysis by Matsumoto
et al.14 of the accuracy of FDG-PET in detecting pancreatic
cancer found that only 69% of tumours less than 20 mm were
detected. Additionally, 79% of focal, mass-forming pancreatitis
cases were FDG avid. In contrast, a large meta-analysis of 38
studies found that both FDG PET and PET/CT detected
primary pancreatic cancers with high sensitivity of around
90%, but with a somewhat lower specificity, around 80%.16
Sensitivity and specificity values might be misleading as they
will be impacted by subjective interpretation of a ‘positive
scan’ which might be biased in retrospective analyses, and by
the chosen benchmark used to define the true diagnosis
(biopsy versus follow-up etc.). It is noteworthy that in five
patients in our study with mild to moderately FDG avid
primary tumours, PET/CT was still able to detect metastases.
The highest region of FDG uptake may be around the biliary
stent. Of course this may be as a result of malignant cells
within the tumour but it is conceivable that a stent-induced
inflammation/immune reaction may contribute. Of note, 3/28
stented patients had a separate tumour mass exhibiting a lower
SUV than was seen around the stent. This concept should be
considered when interpreting PET/CT images. Given there is
increasing interest in using PET/CT scanning as an early
marker of treatment response, perhaps to guide subsequent
management17, our data may have implications for pancreatic
research protocols investigating PET/CT scanning in the neo-
adjuvant or locally advanced settings. Specifically, FDG uptake
around the stent may not be due to malignant cells, and hence
may not reflect the efficacy of chemo/targeted therapy, thereby
confounding data interpretation. It is important to emphasize,
however, that our results are not definitive. We did not corre-
late SUV around stents with histological parameters and we
have not assessed the possible confounding effects, if any, of the
type of stent or time from stent insertion to PET/CT scanning
on SUV uptake.
In conclusion, this prospective study was specifically
designed to examine the value of FDG PET/CT in resectable
pancreatic cancer, in real world clinical practice. We feel that
our study design possesses considerable strengths in compari-
son to other retrospective analyses. PET/CT, notwithstanding
the shortcomings discussed, detects metastatic disease in a sig-
nificant percentage of patients. Consequently, we intend to
incorporate PET/CT into our diagnostic algorithm for these
patients. Further research is needed with the aim of refining
patient selection for surgery. To this end, we plan on investi-
gating novel gallium-68 labelled PET tracers targeting chemokine
receptors.
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